Melanotan 1 10mg

Melanotan 1 mimics alpha-MSH to stimulate melanocyte activity, increasing pigmentation and providing sunless tanning benefits. It also influences metabolism through melanocortin receptors, offerMelanotan 1, also known as Afamelanotide, is a synthetic analogue of the naturally occurring alpha-melanocyte stimulating hormone (α-MSH). It primarily influences melanocytes, the cells responsible for pigmentation in skin and hair. Melanotan 1 has been utilized in clinical settings, particularly in Europe, to prevent sun-related skin damage, such as phototoxicity in individuals with erythropoietic protoporphyria.

Melanotan 1 Research

Melanotan 1 Originally Designed for Sunless Tanning

MT-1 has undergone phase 1 clinical trials to study its effects on tanning in humans exposed to ultraviolet radiation. The research demonstrated that subjects administered MT-1 were 75% more likely to tan and 47% less likely to experience sunburn. Compared to control groups, participants given melanotan 1 required 50% less ultraviolet light exposure to achieve the same level of tanning. Additionally, their tan lasted three weeks longer than those exposed only to UV light. Some scientists believe melanotan 1 could enhance tanning in high UV environments, providing protection against sunburn and the long-term damage caused by ultraviolet exposure. 

This may be especially beneficial for individuals with poor tanning skin types (classified as type I and type II on the Fitzpatrick scale). Studies in individuals with variant MC1 receptors show they are less likely to tan than average. Interestingly, administering melanotan 1 in these cases significantly increases melanin density and tanning, offering protection to people who tan poorly and thus need photoprotection the most. These individuals often gain limited benefit from sunscreen and must greatly limit sun exposure to prevent skin cancer. This research could lead to improved UV protection methods and potentially reduce skin cancer rates substantially.

There is also interest in using melanotan 1 to treat vitiligo. A small phase 1 trial indicated that combining melanotan 1 with UVB light therapy stimulated melanin production and promoted the proliferation of melanocytes, the cells responsible for producing melanin. Nearly half of the treated patients showed improved pigmentation of vitiligo lesions and experienced faster repigmentation. Studies suggest that combining melanotan 1 with existing vitiligo treatments produces synergistic effects and better aesthetic outcomes in shorter timeframes. If successful, melanotan 1 could also be applied to treat hypopigmented scars and similar conditions.

Actinic keratosis, also known as solar keratosis, is a crusty, scaly skin growth caused by excessive UV exposure. It is considered a precancerous lesion that, if left untreated, can develop into squamous cell carcinoma, a form of skin cancer. Over 400,000 cases occur annually. While visible lesions can be removed by dermatologists or surgeons, most are too small to see or feel. Melanotan 1 is being explored as a potential first-line treatment for these invisible lesions and for preventing their progression to full-blown skin cancer.

Melanotan-1 Research and Blood Pressure

Research on hypertensive (high blood pressure) mice has shown that melanotan 1 can protect against elevated blood pressure without affecting animals with normal blood pressure. This is significant because current blood pressure medications can cause hypotension, which may lead to loss of consciousness, stroke, heart attack, and other complications. This side effect is especially common in the elderly due to their labile physiology. The ability of melanotan 1 to regulate high blood pressure without causing dangerously low blood pressure makes it an ideal candidate for further drug development.

Cognitive Decline, Alzheimer’s Disease, and Melanotan 1

Studies in transgenic mice suggest that melanotan 1 may protect the brain from damage associated with cognitive decline and Alzheimer’s disease. Using a mouse model of moderate Alzheimer’s disease, researchers found that even minute doses of melanotan 1 reduce amyloid beta plaque levels in the brain, protect neurons from death, and improve both clinical cognitive function and laboratory measures of synaptic transmission. Blocking melanotan 1’s effects at the MC4 receptor prevented all these beneficial outcomes. Additional studies indicate that stimulating the MC4 receptor promotes neurogenesis and cognitive recovery in Alzheimer’s models. Daily administration of MT-1 reduces all Alzheimer’s disease-related biomarkers, suggesting it works through multiple pathological pathways.

The MC4 receptor is unique among melanocortin receptors as it is expressed on astrocytes—the cells that protect and nourish neurons. Research in rats shows that melanotan 1 enhances astrocyte function by increasing brain-derived neurotrophic factor (BDNF), which is critical for synapse stability and neurogenesis.

Melanotan 1 and Functional Recovery Following Stroke

Improvements are not limited to Alzheimer’s biomarkers. In gerbil stroke models with ten-minute ischemic episodes, treatment with nanomolar doses of melanotan 1 reduces brain damage, including neuron death, and enhances recovery of learning and memory. Remarkably, these benefits occur even when melanotan 1 is administered nine hours after the stroke. It is believed that MT-1 activates repair mechanisms that boost synaptic plasticity and support lasting functional recovery by rerouting learning and memory to healthier brain areas. The gene Zif268 appears central to this process, being overexpressed in animals treated with melanotan 1 and also in Alzheimer’s models showing cognitive improvement.

Melanotan 1 Influences Heart and Circulation

In rat models of heart attack, melanotan 1 and related melanocortins help reduce injury and improve circulatory function. Administering MT-1 during CPR alongside epinephrine restores baseline arterial pressure and heart rate, reverses metabolic acidosis, lowers inflammatory markers, and enhances expression of genes linked to cardiac function. Overall, this therapy increased survival rates by 81%, suggesting melanotan 1 or similar peptides could become essential in advanced cardiac life support.

Melanotan 1 Research and Neuroinflammatory Disease

Previously, the MC1 receptor was thought to only regulate pigmentation in skin and hair. Recent mouse studies reveal it also modulates inflammation in the central nervous system. For example, in multiple sclerosis, helper T cells cause myelin loss on neurons, leading to dysfunction and death. Melanotan 1 administration in mice disrupts this process, prevents myelin loss, improves myelin recovery, and helps restore neuron signaling. Similar effects occur in mouse models of uveitis, an inflammatory eye disorder that can cause pain and vision loss. Current treatments have many side effects, prompting research into alternatives. Alpha-MSH suppresses T-cell function via the MC4 receptor, mimicked by MT-1. Surprisingly, local MC4 receptor agonist delivery directly to the eye is as effective as systemic administration, reducing systemic side effects.

Melanotan 1 Investigated in Fat Loss Trials

Melanotan 1 acts on several melanocortin receptors, including the MC5 receptor. Stimulating MC5 promotes fatty acid oxidation by muscle and shifts fat cells from storage to burning. These findings in mice show fat burning involves multiple receptors and physiological pathways. Melanotan 1 offers scientists a way to explore altering fatty acid metabolism and presents the potential to boost baseline metabolism without exercise, which could benefit individuals unable to exercise due to obesity, disability, or injury.

Research Applications

Melanotan 1 is primarily utilized in scientific studies focusing on:

• Skin Pigmentation: Investigating its role in enhancing skin tanning and pigmentation.
• Melanocortin Receptor Activity: Studying its effects on melanocortin receptors and related pathways.
• Metabolic Research: Exploring its influence on metabolism and related physiological processes.

Product Specifications

• Form: Lyophilized (freeze-dried) powder for reconstitution.
• Dosage: Each vial contains 10mg of Melanotan 1.
• Purity: Typically ≥99%, ensuring high-quality material for research purposes.
• Packaging: Available in sealed vials containing 10mg of Melanotan 1 powder.
• Storage: Store lyophilized Melanotan 1 at temperatures below -18°C. After reconstitution, store at 4°C and use within 2-7 days.

Safety and Handling

Melanotan 1 is intended strictly for laboratory research and is not approved for human consumption. Handle with care, following appropriate safety protocols. Ensure proper storage conditions to maintain the integrity and efficacy of the compound.ing skin protection and enhancing natural pigmentation. Achieve a beautiful, healthy glow safely with Melanotan 1. Purchase now for radiant skin year-round!

References

• “Effects of a Superpotent Melanotropic Peptide in Combination With Solar UV Radiation on Tanning of the Skin in Human Volunteers | Dermatology | JAMA Dermatology | JAMA Network™ 
• “Effect of MELANOTAN, [Nle(4), D-Phe(7)}-alpha-MSH, on melanin synthesis in humans with MC1R variant alleles.” PubMed - NCBI [Accessed: 24-Jun-2019] 
• “Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial.” Medscape Abstract [Accessed: 24-Jun-2019] 
• “Advances in Vitiligo: An Update on Medical and Surgical Treatments.” Medscape Abstract [Accessed: 24-Jun-2019] 
• “α-MSH analogue attenuates blood pressure elevation in DOCA-salt hypertensive mice.” PubMed - NCBI [Accessed: 24-Jun-2019]
• “Melanocortins protect against brain damage and counteract cognitive decline in a transgenic mouse model of moderate Alzheimer's disease.” PubMed - NCBI [Accessed: 24-Jun-2019]
• “NDP-α-MSH induces intense neurogenesis and cognitive recovery in Alzheimer transgenic mice through activation of melanocortin MC4 receptors.” PubMed - NCBI [Accessed: 24-Jun-2019]
• “Melanocortins protect against progression of Alzheimer’s disease in triple-transgenic mice by targeting multiple pathophysiological pathways.” PubMed - NCBI [Accessed: 24-Jun-2019]
• “Melanocortin 4 receptor activates ERK-CFos pathway to increase brain-derived neurotrophic factor expression in rat astrocytes and hypothalamus.” PubMed - NCBI [Accessed: 24-Jun-2019]
• “Functional recovery after delayed treatment of ischemic stroke with melanocortins is associated with overexpression of the activity-dependent gene...” PubMed - NCBI [Accessed: 24-Jun-2019]
• “Protective effects of the melanocortin analog NDP-α-MSH in rats undergoing cardiac arrest.” PubMed - NCBI [Accessed: 24-Jun-2019]
• “Melanocortin-1 receptor activation is neuroprotective in mouse models of neuroinflammatory disease.” PubMed - NCBI [Accessed: 24-Jun-2019]
• “Immunosuppressive activity of a novel peptide analog of α-melanocyte stimulating hormone (α-MSH) in experimental autoimmune uveitis.” PubMed - NCBI [Accessed: 24-Jun-2019]
• “Peripheral effect of alpha-melanocyte-stimulating hormone on fatty acid oxidation in skeletal muscle.” PubMed - NCBI [Accessed: 24-Jun-2019]
• “Characterization of murine melanocortin receptors mediating adipocyte lipolysis and examination of signalling pathways involved.” PubMed - NCBI [Accessed: 24-Jun-2019]